PreludeDx™ to Present Multiple Presentations at the 2023
PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS)....
Source: globenewswire.com
📰 Breast Conserving News
Breast Conserving News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Breast Conserving. Real-time updates on events, politics, business and more.
PreludeDx™ to Present DCISionRTÒ and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting
/PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...
Source: prnewswire.com
PreludeDx™ to Present DCISionRT® and Novel Residual Risk Subtype Study Results During Scientific Oral Session at ASBrS 2022 Annual Meeting
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...
Source: prnewswire.com
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients 42% change in treatment recommendations when using DCISionRT News provided by Share this article Share this article LAGUNA HILLS, Calif., April 21, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced results for a prospective study in 44 U.S. academic and community cancer centers that eva...
Source: prnewswire.com